IMPROVING OUTCOMES IN LETHAL PROSTATE CANCER THROUGH GUIDELINE-CONCORDANT USE OF BONE-MODIFYING AGENTS

$1,248,613FY2021Defense Health AgencyDOD

Sloan-Kettering Institute For Cancer Research

Investigators